# Eosinophilic Pneumonia

Confirm pulmonary eosinophilia, triage hypoxemic acute disease, and identify an exposure, drug, infection, systemic disorder, or chronic idiopathic pattern before committing to corticosteroid treatment.

**Clinical question:** How should physicians confirm eosinophilic pneumonia, distinguish its causes, and prioritize urgent management?

Updated: 2026-08-24T16:11:51.478432+00:00

## What matters in practice
- Bronchoalveolar lavage (BAL) eosinophils >25% in a compatible pulmonary syndrome support eosinophilic pneumonia; BAL >40% particularly favors chronic eosinophilic pneumonia (CEP). [17][23]
- Acute eosinophilic pneumonia (AEP) is an urgent hypoxemic illness that can resemble severe community-acquired pneumonia or ARDS; peripheral eosinophilia may be absent early. [20][22][23]
- Before labeling disease idiopathic or initiating corticosteroids, actively exclude a culprit medication, inhalational exposure, fungal or helminthic infection, allergic bronchopulmonary aspergillosis, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome. [20][22]
- Lung biopsy is usually unnecessary when compatible imaging and pulmonary eosinophilia establish the diagnosis; reserve biopsy for discordant clinical, laboratory, and imaging findings or unresolved etiologic uncertainty. [17][21]

## Triage hypoxemia and establish pulmonary eosinophilia

Treat acute respiratory failure in parallel with diagnostic bronchoscopy and etiologic exclusion.

In a patient with new pulmonary opacities and respiratory symptoms, obtain room-air oxygenation and assess for an AEP phenotype: febrile respiratory illness lasting no more than 1 month, bilateral infiltrates, and severe hypoxemia defined by PaO2 <60 mm Hg, PaO2/FiO2 ≤300 mm Hg, or room-air oxygen saturation <90%. This presentation can progress to ARDS and may be mistaken for severe community-acquired pneumonia. [20][22]

Confirm lung eosinophilia with bronchoscopy and BAL when clinically feasible. A BAL eosinophil differential >25% is diagnostic in a compatible setting; a proportion >40% is found mainly in CEP. BAL eosinophils between 3% and 40% are less specific and occur in other interstitial lung diseases, so interpret subthreshold results with the imaging pattern, peripheral eosinophil count, exposure history, and microbiology. [17][23]

Do not exclude AEP because the admission complete blood count lacks eosinophilia. Peripheral eosinophilia may be absent or mild early in AEP and may also be suppressed by antecedent corticosteroids. When using blood eosinophilia as the principal evidence of pulmonary eosinophilic disease, an absolute eosinophil count >1 × 10^9/L with typical clinical-radiologic features is more persuasive; counts >1.5 × 10^9/L further support the diagnosis. [17][21][23]
- Obtain chest radiography initially; use chest CT when the distribution of consolidation or ground-glass opacity will help distinguish eosinophilic pneumonia from organizing pneumonia, vasculitis, infection, or another interstitial process. [19][21]
- In acute hypoxemia, send infectious testing and obtain BAL fluid for differential cell count and microbiologic evaluation before attributing diffuse infiltrates to idiopathic AEP. [20][22]
- If bronchoscopy is unsafe or BAL is nondiagnostic, biopsy can demonstrate eosinophilic pneumonia; pursue tissue particularly when the clinical, biologic, and imaging findings conflict. [17][20][21]

*Pulmonary eosinophilia thresholds and their diagnostic use. [17][21][23]*

| Finding | Threshold or pattern | Interpretation and next action |
| --- | --- | --- |
| Peripheral blood eosinophilia | >0.5 × 10^9/L (500/µL) [21] | Supports eosinophilic disease but can be absent in early AEP; obtain BAL if pulmonary eosinophilia remains suspected. [21][23] |
| Blood eosinophilia with pulmonary opacities | >1 × 10^9/L; preferably >1.5 × 10^9/L [17][21] | Can support eosinophilic pneumonia when clinical and HRCT findings are compatible; still determine the cause. [17][21] |
| BAL eosinophils | >25% [17][20][21] | Supports eosinophilic pneumonia and usually avoids surgical lung biopsy in a compatible setting. [17] |
| BAL eosinophils | >40% [17][23] | Pattern is especially associated with CEP; assess for a subacute course and peripheral consolidation. [17][23] |

## Separate acute eosinophilic pneumonia from chronic eosinophilic pneumonia

Time course, oxygenation, blood eosinophils, and CT distribution determine the immediate branch.

Classify as probable AEP when illness is acute, febrile, and hypoxemic with diffuse bilateral radiographic opacities and BAL eosinophils >25%, after excluding infection and another defined eosinophilic lung disease. Modified criteria define definite AEP by respiratory illness of 1 month or less, pulmonary infiltrates on radiography or CT, pulmonary eosinophilia, and no alternative specific eosinophilic disorder. [20][22]

Classify as CEP when respiratory symptoms have persisted for 2 to 4 weeks with marked tissue and peripheral blood eosinophilia and alveolar consolidation with air bronchograms and/or ground-glass opacities. The combination of peripheral consolidation, blood eosinophilia, BAL eosinophilia, and corticosteroid response is often sufficient without biopsy. [18][19]

When imaging suggests CEP but organizing pneumonia remains plausible, favor CEP when eosinophilia is prominent in blood or BAL. Compared with CEP, organizing pneumonia more often has peribronchovascular consolidation and a reverse-halo sign; mild BAL eosinophilia can occur in cryptogenic organizing pneumonia and should not alone establish CEP. [17][19]
- AEP: pursue an urgent exposure and medication history, because recent inhalational exposure and medications may identify a reversible secondary trigger. [6][16][22]
- CEP: look specifically for asthma and for systemic features that would redirect evaluation toward EGPA rather than lung-limited idiopathic disease. [17][21]
- Reassess after corticosteroid taper in CEP because relapse is common and may require long-term maintenance corticosteroid therapy. [5][19]

*Clinical discriminators between acute and chronic eosinophilic pneumonia. [18][19][20][22][23]*

| Feature | AEP | CEP |
| --- | --- | --- |
| Time course | Acute febrile respiratory illness lasting ≤1 month. [20][22] | Respiratory symptoms for 2–4 weeks. [18][19] |
| Oxygenation | Often severe hypoxemia; PaO2 <60 mm Hg, PaO2/FiO2 ≤300, or room-air saturation <90% is part of commonly used criteria. [22] | Diagnosis is driven by subacute symptoms, eosinophilia, and characteristic alveolar imaging rather than the acute hypoxemic criteria used for AEP. [18][19] |
| Peripheral eosinophils | May be absent or mild initially. [17][23] | Typically marked in tissue and peripheral blood. [18][19] |
| BAL profile | >25% eosinophils supports diagnosis. [20][23] | Often >40% eosinophils. [17][23] |
| Course after corticosteroids | Typically rapid response without relapse or long-term sequelae in diagnostic descriptions. [20] | Rapid response but a tendency to recurrence, particularly during or after taper. [5][19] |

## Identify secondary eosinophilic lung disease before assigning an idiopathic diagnosis

A positive BAL establishes lung eosinophilia, not its cause.

Take a medication and substance history that captures recently started prescription agents, over-the-counter products, illicit drugs, tobacco changes, vaping, cannabis exposure, and other inhalational exposures. Drugs recognized in reports of eosinophilic pneumonia include daptomycin, minocycline, venlafaxine, ranitidine, paracetamol, and allopurinol; discontinue a plausible culprit rather than continuing exposure while treating a presumed idiopathic syndrome. [6][14][22]

Select infection testing from exposure history before corticosteroid treatment when possible. For relevant fungal exposure, evaluate for Aspergillus and Coccidioides with culture, microscopy, or serologic studies; for relevant parasite exposure, evaluate especially for Strongyloides. Aspergillus infection can clinically mimic AEP but requires antifungal treatment rather than treatment directed solely at eosinophilic inflammation. [22]

Screen for systemic eosinophilic disorders when pulmonary disease coexists with asthma, chronic sinonasal disease, neuropathy, extrapulmonary organ involvement, or marked persistent eosinophilia. EGPA can produce peripheral or random ground-glass opacities and consolidations; ANCA is positive in approximately 40% of cases, predominantly p-ANCA with myeloperoxidase activity, so a negative ANCA does not exclude EGPA. [21]
- For suspected EGPA, assess asthma, peripheral eosinophilia >10% of leukocytes, neuropathy, pulmonary opacities, paranasal sinus abnormalities, and biopsy evidence when tissue is obtained; these are components of the American College of Rheumatology classification approach described in the literature. [21]
- Exclude allergic bronchopulmonary aspergillosis, hypereosinophilic syndrome, and EGPA specifically before diagnosing AEP under modified criteria. [20]
- Consider hematologic malignancy, allergic disorders, autoimmune disease, parasitic infection, and fungal infection when eosinophilic lung disease is not explained by a medication or inhalational trigger. [10]

*Etiologic branches that change testing and management. [6][10][20][21][22]*

| Etiologic branch | Discriminator | Immediate next step |
| --- | --- | --- |
| Drug-induced eosinophilic pneumonia | Temporal relation to a newly prescribed or suspect medication; implicated agents include daptomycin and minocycline. [6][14][22] | Stop the suspected agent and document the adverse pulmonary reaction. [22] |
| Inhalationally associated AEP | Recent tobacco, vaping, cannabis, or other inhalational exposure in an acute hypoxemic syndrome. [16][22] | Stop exposure and complete infectious exclusion while managing hypoxemia. [16][22] |
| Fungal or helminthic infection | Relevant geographic, environmental, or travel exposure; fungal disease or Strongyloides can mimic eosinophilic lung disease. [22] | Obtain targeted cultures, microscopy, and/or serologies before diagnosing idiopathic disease. [22] |
| EGPA | Asthma, eosinophilia, neuropathy, sinus disease, pulmonary opacities, or compatible biopsy; ANCA may be negative. [21] | Obtain ANCA with myeloperoxidase specificity and assess systemic organ involvement. [21] |
| Hypereosinophilic syndrome or hematologic disease | Persistent marked eosinophilia or extrapulmonary organ involvement without an exposure or infection. [10][20] | Pursue systemic and molecular evaluation rather than treating as lung-limited idiopathic disease. [10] |

## Remove the trigger, support gas exchange, and use corticosteroid response as a clinical checkpoint

Treatment urgency tracks hypoxemia, while definitive management depends on the etiologic branch.

For suspected AEP with severe hypoxemia, provide oxygen and escalate ventilatory support as required while completing bronchoscopy and infectious evaluation. AEP can present as ARDS, and reported diagnostic frameworks include prompt corticosteroid response as a characteristic feature; however, infection and alternative eosinophilic syndromes must be excluded rather than inferred from steroid responsiveness alone. [20][22]

For CEP, corticosteroid therapy commonly produces a rapid clinical response, but relapse after tapering is a defining management problem. Monitor symptoms, oxygenation, chest imaging, and peripheral eosinophil counts during dose reduction; recurrent disease may require long-term maintenance corticosteroid therapy. [5][19]

For drug-associated disease, withdrawal of the suspected medication is the essential cause-directed action. For infection-associated disease, redirect therapy to the identified pathogen; do not use clinical eosinophilia or a transient corticosteroid response to substitute for fungal or helminthic testing in an exposed patient. [6][22]
- Document baseline room-air oxygen saturation or arterial oxygenation before treatment in suspected AEP, because hypoxemia thresholds help establish severity and guide escalation. [22]
- Repeat blood eosinophil counts after acute treatment, recognizing that initial AEP counts may have been normal and that corticosteroids can suppress eosinophilia. [17][23]
- Obtain repeat chest imaging when symptoms or oxygenation fail to improve as expected, when relapse occurs during taper, or when an alternative diagnosis such as organizing pneumonia remains plausible. [19]

## Use pathology selectively when BAL and clinical pattern do not resolve the diagnosis

Biopsy should answer a specific unresolved question, not duplicate diagnostic BAL.

A compatible syndrome with BAL eosinophilia >25% generally obviates video-assisted thoracoscopic surgical lung biopsy. Reserve biopsy for inconsistency among clinical course, laboratory data, and imaging; tissue can confirm eosinophilic pneumonia and may distinguish competing processes such as vasculitis, organizing pneumonia, malignancy, or another interstitial lung disease. [17][20][21]

If BAL eosinophils are below 25% but suspicion remains high, do not treat the threshold as an absolute exclusion. BAL can be affected by prior corticosteroid exposure, and lung biopsy is a reasonable alternative when a definitive diagnosis will alter therapy or when imaging is atypical. [15][17]

Escalate evaluation beyond a lung-limited diagnosis when pulmonary eosinophilia accompanies neuropathy, sinonasal disease, asthma, marked blood eosinophilia, or other organ involvement. In these settings, pathology and directed immunologic or molecular testing may identify EGPA, hypereosinophilic syndrome, malignancy, or another systemic cause. [10][21]

## References
1. 2 — www.fda.gov — https://www.fda.gov/media/177921/download
2. Final for posting_with WG edits — www.fda.gov — https://www.fda.gov/media/135307/download
3. Acute Eosinophilic Pneumonia Among US Military ... — jamanetwork.com — https://jamanetwork.com/journals/jama/fullarticle/200056
4. Demystifying Idiopathic Interstitial Pneumonia — jamanetwork.com — https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/214936
5. Optimal dose of maintenance steroid therapy for relapse ... — bmjopenrespres.bmj.com — https://bmjopenrespres.bmj.com/content/12/1/e002697
6. Exploratory disproportionality analysis of potentially drug-induced eosinophilic pneumonia using United States Food and Drug Administration adverse event reporting system | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-025-85681-0
7. Acute lung injury—from cannabis to COVID — www.nature.com — https://www.nature.com/articles/s41379-021-00915-6
8. Diagnosis and management of drug-associated interstitial ... — www.nature.com — https://www.nature.com/articles/6602064
9. Prognostic value of the platelet, neutrophil, monocyte, basophil, and eosinophil to lymphocyte ratios in patients with severe community-acquired pneumonia (SCAP) | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-024-80727-1
10. Differential Diagnosis of Eosinophilic Lung Diseases — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2213219826000784
11. Redefining Interstitial Lung Disease Diagnosis Through the ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0012369226009438
12. Diagnóstico y tratamiento de las enfermedades ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S030028960375457X
13. Acute Eosinophilic Pneumonia Alterations in Smoking ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0012369215517510
14. Drug-induced eosinophilic pneumonia: A review of 196 case... : Medicine — journals.lww.com — https://journals.lww.com/md-journal/fulltext/2018/01260/drug_induced_eosinophilic_pneumonia__a_review_of.22.aspx
15. CT-Guided Percutaneous Lung Biopsy in the Diagnosis of Asthma-Associated Chronic Eosinophilic Pneumonia: A Case Report - PubMed — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pubmed/41458325
16. ACUTE EOSINOPHILIC PNEUMONIA - CHEST — journal.chestnet.org — https://journal.chestnet.org/article/S0012-3692(24)01922-6/fulltext
17. Eosinophilic Pneumonia - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121898
18. Acute and chronic eosinophilic pneumonia: an overview - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11070545
19. Acute and chronic eosinophilic pneumonia: an overview — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11070545
20. Acute Eosinophilic Pneumonia. Causes, Diagnosis, and Management — www.atsjournals.org — https://www.atsjournals.org/doi/10.1164/rccm.201710-1967CI
21. Pulmonary Eosinophilia - StatPearls - NCBI Bookshelf - NIH — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK470600
22. Acute Eosinophilic Pneumonia - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC3591538
23. Bronchoalveolar lavage as a diagnostic procedure: a review of known cellular and molecular findings in various lung diseases — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC7578496
24. Chronic Eosinophilic Pneumonia in an Adolescent Without ... — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12433688

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.